Michal Wlodarski, Camin examines the manufacturing challenge of antibody-drug conjugates
Traditionally afflictions such as cancer, autoimmune diseases and inflammatory disorders have been treated with small molecule compounds that lack cell-targeting and thus have profound systemic implications. A well-known example is a chemotherapeutic agent. These compounds often have detrimental non-specific effects which, together with their prolonged multi-dose administration and systemic exposure, yield severe side-effects. In addition, such drugs often have very low therapeutic indexes where the window between the drug’s effective and toxic dose is narrow, making the optimal dosing a significant challenge for the clinicians, and ultimately deteriorating treatment outcomes and patient’s wellbeing.